Figure 2 | British Journal of Cancer

Figure 2

From: Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma

Figure 2

Pharmacokinetics of ZD6126 (A) and ZD6126 phenol (B) after administration of free and liposomal ZD6126 in non-tumour-bearing C57Bl/6 mice. Formulations were injected in a single bolus intravenous dose of 20 mg kg−1. Groups (n=3) consisted of free ZD6126 (), PEG-liposomal ZD6126 (▴), and RGD-PEG-liposomal ZD6126 (). At selected time point, post-injection blood was collected and ZD6126 and ZD6126 plasma levels were measured by tandem mass spectrometry. All points are averages of three mice±s.d. Additionally, AUC values t1/2, Cmax and Tmax values were calculated.

Back to article page